Management Team

Experienced and accomplished team of leaders
with proven track record
.
Manager
 
     
 
  Management Team of Affimed  
   
 
 
  Dr. Adi Hoess
Chief Executive Officer
Dr. Florian Fischer
Chief Financial Officer
Dr. Martin Treder
Chief Scientific Officer
Dr. Anne Kerber
Chief Medical Officer (interim)
Dr. Jörg Windisch
Chief Operating Officer
 
 
 
 
   

 

Dr. Adi Hoess

  Chief Executive Officer
 
Dr. Hoess joined Affimed in October 2010 as Chief Commercial Officer and since September 2011 has led the company as CEO. He has more than 20 years of professional experience with an extensive background in general management, business development, product commercialization, fund raising and M&A. Prior to joining Affimed, Dr. Hoess was Chief Commercial Officer at Jerini AG and CEO of Jenowis AG. At Jerini AG he was responsible for BD and the market introduction of Firazyr. He also played a major role in the M&A process of Jerini AG with Shire. From 2000 – 2002 Dr. Hoess was General Manager and VP of the Molecular Medicine Division at Carl-Zeiss in Jena. Dr. Hoess began his professional career in 1993 at MorphoSys as scientist. In 1997 he became Director of BD and in 1999, VP of Licensing and BD.

Dr. Hoess received his PhD in chemistry and biochemistry from the University of Munich in 1991, and he also received an M.D. from the Technical University (TU) of Munich in 1997. From 1991 until 1993 Dr Hoess work as a post doc at the Dana-Farber Cancer Institute at the Harvard Medical School in Boston, USA.

 
   

 

Dr. Martin Treder

  Chief Scientific Officer
 
Starting his position in January 2015 Dr. Treder is responsible for the further development of Affimed’s proprietary bi- and trispecific TandAb platforms, the expansion of the company’s internal pipeline and furthermore providing scientific support for its clinical programs and for collaborations with corporate partners.

Dr. Treder has 13 years of professional experience in the field of biotherapeutic research and development and broad experience in immuno-oncology discovery and pre-clinical development of antibodies. He joined the Affimed Management Team from CT Atlantic AG, a Swiss biotechnology company focused on the identification and development of human-derived monoclonal antibodies for the treatment of cancer. As co-founder and Chief Scientific Officer he was responsible for establishing a broad research pipeline of various preclinical and clinical development programs.

Prior to CT Atlantic Dr. Treder was co-founder of U3 Pharma AG, a German biotech company developing targeted cancer therapeutics, and held the position of Program Director where he was responsible for heading the company’s portfolio of innovative anti-HER3 therapeutic antibodies. 

Dr. Treder graduated with Honors from Monash University in Melbourne, Australia and obtained a diploma in Biology at the  University of Würzburg, Germany. He earned his PhD working in Prof. Axel Ullrich's group at the Max Planck Institute of Biochemistry in Martinsried-Munich, Germany.

 
   

 

Dr. Jörg Windisch

  Chief Operating Officer
 
Dr. Windisch joined Affimed in February 2016 and is responsible for late-stage technical development, manufacturing, regulatory affairs, quality and project management to support Affimed’s expanding clinical pipeline. He has an extensive biotechnology and biological medicines background, with in-depth expertise in technical development, manufacturing and regulatory affairs. Prior to joining Affimed, Dr. Windisch spent 20 years at Sandoz Biopharmaceuticals (a Novartis company), most recently serving as Chief Science Officer. He joined Novartis in 1996 in the biologics unit of Sandoz, where he played a leading role in the development of Somatropin (Omnitrope®), the first ever biosimilar medicine, as well as of Sandoz’ Epoetin alfa (Binocrit®) and Filgrastim (Zarzio®) products.

Over the course of 15 years he built an international technical development organization for biologics and, for five years, Dr. Windisch also led the joint biologics technical development and manufacturing organization for Novartis Pharma and Sandoz. He was involved in the development and manufacturing of about 20 biologics, several of which are currently marketed. Dr. Windisch was educated in Austria, Germany, and the US and received his Ph. D. in Biochemistry and Molecular Genetics from the University of Innsbruck.
 
   

 

Dr. Florian Fischer
MBA (Dipl.-Kfm.)

  Chief Financial Officer
 
Dr. Fischer joined Affimed in 2005 as CFO on a part-time basis. Since September 2014, Dr. Fischer is fulltime employed by Affimed. He has a strong track record in various Biotech/MedTech executive positions, as lead advisor in a variety of transactions and financings in the life sciences and healthcare sector.

Dr. Fischer is founder of MedVenture Partners - a corporate finance and strategy advisory company focusing on the life sciences and healthcare industry. Dr. Fischer was Chief Financial Officer of Activaero GmbH from 2002 until 2011 and responsible for corporate development until the acquisition by Vectura in 2014. He also served as Chief Financial Officer of Vivendy Ltd. from 2008 until 2013 and as managing director of AbCheck in 2009. Prior to founding MedVenture Partners, Dr. Fischer worked with KPMG for more than six years until 2002, where he was responsible for biotech and healthcare assignments. Before joining KPMG, he worked for Deutsche Bank AG. Dr. Fischer is also a Director of Amphivena.

He holds a graduate degree in business administration from Humboldt University, Berlin and a Ph.D. in public health from the University of Bielefeld.
 
   

 

Dr. Anne Kerber

  Vice President Medical/Interim CMO
 
Dr. Kerber joined Affimed in January 2016 as Senior Medical Director and Head of Operations. She was appointed Vice President Medical in August 2016, also leading the Company’s clinical development team as interim CMO. Dr. Kerber joined Affimed from Merck KGaA, where she held multiple positions in clinical development, most recently as Global Clinical Lead for EGFR-targeting therapies. At Merck, she was responsible for developing both early and late stage clinical development strategies for novel chemical and biological entities in various cancer indications including glioblastoma, lung, head and neck, colorectal, and prostate cancers, as well as other solid tumors. Dr. Kerber acted as medical representative in global product teams and has a strong track record in designing and conducting Phase 1-3 clinical studies in Europe, the US, China and Japan. During her academic career, she was an investigator in numerous clinical studies in oncology including gastrointestinal, breast, ovarian, and lung cancer, as well as lymphomas.

Dr. Kerber holds an M.D. from the University of Marburg, Germany and became a board certified Internist and Hematologist/Oncologist at the University Hospital and at Nordwest Hospital, respectively, both in Frankfurt/Main, Germany. Additionally, she holds a degree in Pharmaceutical Medicine, from the University Basel, Switzerland.

 
 
     



 
  Impressum Disclaimer